


Spotlight on Research Fees: Planned Subjects per Phase 4 Site

By Rafael A Campo

In the period 2007-2012, the average number of planned subjects per site in a Phase 4 trial, across 13 selected therapeutic areas, was 24 subjects. Devices and diagnostics (70), Anti-Infective (60), Cardiovascular (49), and Dermatology (42) had the highest average numbers of planned subjects. Hematology (8), Endocrine (9), and Gastrointestinal (11) had the lowest average numbers.

Planned Subjects per Site for Phase 4 Studies

(Average Planned Subjects by Therapeutic Areas, Phase 4, Worldwide Industry-Sponsored Pharmaceutical, Biotechnology, Device and Diagnostics Studies, 2007-2012)¹



Medidata Solutions, Inc.

Notes & References

1. Source: Medidata Grants Manager™, the PICAS® database

Author

Rafael A Campo is the Manager of Data Quality and Analytics at Medidata Solutions, Inc. Contact him at 1.215.358.1429 or rcampo@mdsol.com.